Roche secures rights to Alector's Parkinson's therapy for up to $1.27 billions, Alector shares surge
路透社2026/10/05 12:16Reuters, October 5 – U.S. biotechnology company Alector announced on Monday that Swiss pharmaceutical giant Roche will pay up to 1.27 billion dollars to obtain licensing rights for its experimental Parkinson's disease therapy. Boosted by this news, Alector’s shares surged 72% in pre-market trading. Genentech, a subsidiary of Roche, will pay Alector a 100 million dollar upfront payment, with an additional payment of up to 1.17 billion dollars if the therapy meets certain developmental, regulatory, and sales milestones. Alector will also receive royalty payments. Specific details are as follows: the agreement grants Genentech exclusive global rights to develop, produce, and commercialize AL050, an experimental therapy targeting enzyme deficiency associated with Parkinson’s disease. Genentech will be responsible for the development, regulatory filings, production, and commercialization of the therapy. AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency—which leads to the buildup of certain fats and increases the risk of Parkinson’s. This deal is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline. In June, Roche and Nurix Therapeutics entered into a licensing and collaboration agreement involving a blood cancer medication, with a deal value of up to 2.3 billion dollars.
Reuters, October 5 - US biotechnology company Alector announced on Monday that Swiss pharmaceutical company Roche ROPC.S will pay up to $1.27 billion to acquire the rights to its experimental Parkinson's disease therapy ALEC.O, boosting the company's share price by 72% in pre-market trading.
Roche's subsidiary Genentech will pay Alector an upfront payment of $100 million, and if the therapy meets research, regulatory, and sales targets, an additional payment of up to $1.17 billion will be made. Alector will also receive royalty payments.
Details are as follows:
The agreement grants Genentech exclusive global rights to develop, manufacture, and sell AL050, an experimental therapy aimed at addressing enzyme deficiency associated with Parkinson's disease.
Genentech will be responsible for the development, regulatory filings, manufacturing, and commercialization of the therapy.
AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency — this deficiency can lead to the accumulation of certain fats and increase the risk of Parkinson's disease.
This transaction is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline.
In June this year, Roche and Nurix Therapeutics NRIX.O entered into a licensing and collaboration agreement (link) involving a blood cancer drug, with a transaction value of up to $2.3 billion.
(For the convenience of non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translations may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated translation text, and provides it solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citigroup: Japanese bond yields may have reached their peak, clearer fiscal outlook will enhance investment appeal
Citigroup strategists believe that Japanese government bond yields may be approaching their peak, and they expect financial institutions to increase investments in Japanese bonds as the country's fiscal policy outlook becomes clearer.
KOSPI Index in South Korea Falls by 1%
CCL three giants' monthly revenue hits record high
Crypto prices
More
